| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 02/25/2004 | EP1390384A2 Chromosome-based platforms |
| 02/25/2004 | EP1390383A1 Antisense permeation enhancers |
| 02/25/2004 | EP1390345A1 Polythiourea lipid derivatives |
| 02/25/2004 | EP1390075A2 Chemotherapeutic induction of egr-1 promoter activity |
| 02/25/2004 | EP1390074A1 Novel compositions and uses therefor |
| 02/25/2004 | EP1390070A1 Use of il-18 inhibitors for treating or preventing cns injuries |
| 02/25/2004 | EP1390064A2 Method of treating malignancies through induction of blood immune responses |
| 02/25/2004 | EP1390060A2 Use of lp82 to treat body weight disorders |
| 02/25/2004 | EP1390059A1 Improved neuronal gene transfer |
| 02/25/2004 | EP1390058A2 Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances |
| 02/25/2004 | EP1390057A2 Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and method of use |
| 02/25/2004 | EP1389909A1 Antimicrobial compounds and methods for their use |
| 02/25/2004 | EP1230223B1 Oligobenzimidazole derivatives and their use as dna transfection agents |
| 02/25/2004 | EP1135481B1 New oligomeric conjugates liable to transfer biological molecules into cells |
| 02/25/2004 | EP0986401B1 P-selectin translocation to vascular epithelial lumen by ionizing radiation |
| 02/25/2004 | EP0981620B1 Hgf polypeptides and their use in therapy |
| 02/25/2004 | EP0820515B1 Phospholipase c homolog |
| 02/25/2004 | EP0751957B1 Peptide fragments of microbial stress proteins and pharmaceutical composition made thereof for the treatment and prevention of inflammatory diseases |
| 02/25/2004 | CN1478147A Composition of carrier granules capable of producing RNA virus and based on RNA virus and its method |
| 02/25/2004 | CN1478146A Calcium binding proteins |
| 02/25/2004 | CN1478143A Tumor cell internal specific proliferated virus capable of high-effectively expressing tumor angiogenesis inhibiting factor and its application |
| 02/25/2004 | CN1477190A Method and relative composition for controlling cell fusion |
| 02/25/2004 | CN1476900A Adjustable controllable tumor eiving vacine and its preparation method |
| 02/25/2004 | CN1476894A SARS epidemic lung tissue cytoplasmic bacterium purified and refined series vacine and its production method |
| 02/25/2004 | CN1139656C Quick high-effective separation and purification method of virus related to recombinant adenovirus and its application |
| 02/24/2004 | US6697837 End user profiling method |
| 02/24/2004 | US6696558 Bag proteins and nucleic acid molecules encoding them |
| 02/24/2004 | US6696423 Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta |
| 02/24/2004 | US6696281 Chimeric flavivirus vaccines |
| 02/24/2004 | US6696273 FEBP1 Protein: vector, host cells and method for making FEBP1 protein |
| 02/24/2004 | US6696272 Products and methods for gaucher disease therapy |
| 02/24/2004 | US6696263 PCNA associated cell cycle proteins, compositions and methods of use |
| 02/24/2004 | US6696089 Nanogel networks including polyion polymer fragments and biological agent compositions thereof |
| 02/24/2004 | US6696062 BASB006 polypeptides from Neisseria meningitidis and immunogenic compositions thereof |
| 02/24/2004 | US6696038 Cationic lipopolymer as biocompatible gene delivery agent |
| 02/24/2004 | CA2219081C Angiostatin fragments and aggregate angiostatin and methods of use |
| 02/19/2004 | WO2004015118A1 Vaccinia virus host range genes to increase the titer of avipoxviruses |
| 02/19/2004 | WO2004015109A1 Human acid sensing ion channel 2b (hasic2b), process for producing the same, and its use |
| 02/19/2004 | WO2004015106A1 Methods to reprogram splice site selection in pre-messenger rnas |
| 02/19/2004 | WO2004015072A2 Mrbs as modifiers of the rb pathway and methods of use |
| 02/19/2004 | WO2004015062A2 Methods and compositions relating to gene silencing |
| 02/19/2004 | WO2004015058A2 Nephritis treatment by gene therapy |
| 02/19/2004 | WO2004014433A1 Inhibition of proliferation and infiltration of brain tumor cells caused by expression of ampa-type glutamate receptor subunit |
| 02/19/2004 | WO2004014312A2 Small-mer compositions and methods of use |
| 02/19/2004 | WO2004014311A2 Nogo receptor antagonists |
| 02/19/2004 | WO2004014306A2 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
| 02/19/2004 | WO2004014302A2 Mechanisms of myoblast transfer in treating heart failure |
| 02/19/2004 | WO2004014301A2 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE |
| 02/19/2004 | WO2004007726A3 Brachyspira hyodysenteriae vaccine |
| 02/19/2004 | WO2003100060A3 Muc-1 antigen with reduced number of vntr repeat units |
| 02/19/2004 | WO2003099193A3 Vaccines |
| 02/19/2004 | WO2003097834A3 A method for in vitro molecular evolution of protein function |
| 02/19/2004 | WO2003095647A3 CHIMERIC snRNA MOLECULES CARRYING ANTISENSE SEQUENCES AGAINST THE SPLICE JUNCTIONS OF THE DYSTROPHIN GENE AND THEIR THERAPEUTIC APPLICATIONS |
| 02/19/2004 | WO2003088979A3 Oligonucleotides from sequences coding for the surface component of envelope proteins of primate t-cell leukaemia/lymphoma viruses (ptlv) and uses thereof |
| 02/19/2004 | WO2003080640B1 Lymphatic and blood endothelial cell genes |
| 02/19/2004 | WO2003078658A3 Methods for diagnosing and treating schizophrenia |
| 02/19/2004 | WO2003069347A3 Diagnostic and therapeutic use of caps |
| 02/19/2004 | WO2003065046A3 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| 02/19/2004 | WO2003055411A3 Implantable device and the use thereof |
| 02/19/2004 | WO2003052051A3 Adeno-associated virus (aav) serotype 8 sequences |
| 02/19/2004 | WO2003049683A3 Use of parapox b2l protein to treat cancer and modify immune responses |
| 02/19/2004 | WO2003040167A3 Peptides which deliver antisense oligonucleotides and downregulate protein expression in cells |
| 02/19/2004 | WO2003018770A3 Amplified oncogenes and their involvement in cancer |
| 02/19/2004 | WO2003012049A3 Methods and composition concerning herpes virus us3 and bad-involved apoptosis |
| 02/19/2004 | WO2003008537A9 Epitope sequences |
| 02/19/2004 | WO2002090514A8 Epidermal growth factor receptorantisense oligonucleotides |
| 02/19/2004 | WO2002083866A3 Repeat sequences of the ca125 gene and their use for diagnostic and therapeutic interventions |
| 02/19/2004 | WO2002061086A3 Human leucine-rich repeat containing protein expressed predominately in small intestine, hlrrsi1 |
| 02/19/2004 | WO2002046477A3 Endogenous retroviruses up-regulated in prostate cancer |
| 02/19/2004 | WO2002042328A3 Method for studying the effects of commensal microflora on mammalian intestine and treatments of gastrointestinal-associated disease based thereon |
| 02/19/2004 | WO2002038738A3 Chimeric molecules to modulate gene expression |
| 02/19/2004 | WO2002024214A3 Use of glp -2 in combination with another therapeutic agent in bone-related and nutrition-related disorders |
| 02/19/2004 | US20040034878 Using transgenic hypercellular nonhuman organisms as cell proliferating gene therapeutic tools |
| 02/19/2004 | US20040034198 Mutant p53 (delta126-132) protein and uses thereof |
| 02/19/2004 | US20040034043 Positively-charged peptide nucleic acid analogs with improved properties |
| 02/19/2004 | US20040033977 Oligonucleotide modulation of cell adhesion |
| 02/19/2004 | US20040033976 Antisense modulation of mekk3 expression |
| 02/19/2004 | US20040033975 Whole cell engineering using real-time metabolic flux analysis |
| 02/19/2004 | US20040033949 Use of VEGF for treating bone defects |
| 02/19/2004 | US20040033605 Using recombinant adenoviral vectors for the delivery and expression of heterologous nucleic acids in nervous system tissues; gene therapy |
| 02/19/2004 | US20040033604 Plasmid coding viral regulatory sequences for use as genetic transfer tool; gene therapy |
| 02/19/2004 | US20040033602 Using small interfering RNA (siRNA) sequences and polypeptides containing enzymatic domains to control gene expression in cell systems; antisense agents |
| 02/19/2004 | US20040033595 Conditionally replicating vectors for inhibiting viral infections |
| 02/19/2004 | US20040033585 Preparing tobbaco mosaic viral particles comprising therapeutic polypeptides for treatment of infectious diseases and tumors; immunotherapy; genetic vaccines |
| 02/19/2004 | US20040033530 High throughput purification, characterization and identification of recombinant proteins |
| 02/19/2004 | US20040033520 Diagnosing metastatic colorectal, stomach and/or esophageal cancer in vitro; immunoassay; radioimaging tumors; immunotherapeutics; genetic vaccines |
| 02/19/2004 | US20040033511 Site-specific antibody-mediated activation of proapoptotic cytokines: AMAIZEe (antibody-mediated apoptosis inducing cytokines) |
| 02/19/2004 | US20040033509 Comprises nucleotide sequences coding enzymatic polypeptides for diagnosis, prevention and treatment of cell proliferative and differentation disorders; antitumor/antisense agents |
| 02/19/2004 | US20040033493 Comprises membrane and/or enzymatic polypeptide for use in prevention, diagnosis and treatment of cancer, diabetes, cardiomyopathy and atherosclerosis; gene therapy |
| 02/19/2004 | US20040033239 Adenovirus formulations |
| 02/19/2004 | US20040033234 Immunogenic polypetides encoded by mage minigenes and uses thereof |
| 02/19/2004 | US20040033230 Breast tumor polypeptides, polynucleotides that encode them, antigen presenting cells that express them, and T cells that are specific for cells that express them. |
| 02/19/2004 | US20040033229 PSMA antibodies and protein multimers |
| 02/19/2004 | US20040033218 Extracellular matrix (ecm); cell and genetic therapy |
| 02/19/2004 | US20040033217 Intraperitoneal delivery of genetically engineered mesenchymal stem cells |
| 02/19/2004 | US20040033214 Pluripotent embryonic-like stem cells, compositions, methods and uses thereof |
| 02/19/2004 | DE10234905A1 Transferring molecules of active agents in cells comprises use of pulsed acoustic waves to generate shear forces on the sample volume containing scattered bodies in vivo or in vitro |
| 02/19/2004 | CA2495121A1 Nogo receptor antagonists |
| 02/19/2004 | CA2495112A1 Mechanisms of myoblast transfer in treating heart failure |
| 02/19/2004 | CA2494908A1 Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |